First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study

Silva, Michael Ruberson Ribeiro da; Santos, Jéssica Barreto Ribeiro dos; Kakehasi, Adriana Maria; Almeida, Alessandra Maciel; Pimenta, Pedro Ricardo Kömel; Alvares-Teodoro, Juliana; Acurcio, Francisco de Assis.
São Paulo med. j ; 140(6): 787-797, Nov.-Dec. 2022. tab, graf
Artigo em Inglês | LILACS-Express | ID: biblio-1410224

Documentos relacionados

  1. First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study.
  2. [Psoriatic arthritis: important aspects for the dermatological practice].
  3. [Rheumatoid arthritis: diagnostics and therapy 2012].
  4. TNF-α blockade may lead to improvement of vascular function in psoriasis patients.
  5. [Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data].
  6. Excimer light effect on neurogenic inflammation in active versus stable psoriasis lesions.
  7. Quality of Life Benefit and Clinical Predictors of Complete Skin Clearance in Psoriasis: A Multicenter, Prospective, Real-World Study.
  8. Long-term efficacy and safety of apremilast in psoriatic arthritis: Focus on skin manifestations and special populations.
  9. Transforming Psoriasis Care: Probiotics and Prebiotics as Novel Therapeutic Approaches.
  10. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).